Pay in 4 interest-free payments of $6.05 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
The SELECT trial, published in 2023, additionally demonstrated that semaglutide reduces the risk of major cardiovascular events in adults with obesity and established cardiovascular disease suggesting cardiovascular benefit that extends beyond weight loss alone
Clinical Studies 14.1 Overview of Clinical Studies The effectiveness of OZEMPIC tablets (1.5 mg, 4 mg and 9 mg strengths) [see Dosage and Administration (2.2)] and RYBELSUS (3 mg, 7, mg and 14 mg strengths) [see Dosage and Administration (2.3)] has been established as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus based on adequate and well-controlled studies of RYBELSUS in adult patients with type 2 diabetes mellitus [see Clinical Pharmacology (12.3)]
[DOI] [PubMed] [Google Scholar] 239.Hamada Y, Yuki K, Okazaki M, Fujitani W, Matsumoto T, Hashida MK, et al
Drugs 50 ObesoJ
US$ 23.15
US$ 25.29
US$ 23.38
US$ 26.49
